MDS 2025: Plenary Session 6: Treatment Low Risk MDS (Part 1)
Session Chairs: Amy E. DeZern and Saskia Langemeijer EPO and Lenalidomide in MDS Non-del(5q) Hege K. Gravdahl Garelius EPO/Lenalidomide in MDS Del(5q) Maria D. Diez-Campelo Luspatercept and TGF beta pathway inhibition Pierre Fenaux Oral Abstracts: Data-Driven Clustering of Low Blasts Patients with Myelodysplastic Syndromes Reveals Biological Features Driving Differences in Prognosis Prediction Carlos Ruiz Arenas The Dark Side of Ring Sideroblasts in Myelodysplastic Neoplasms with Low Blasts Marco G. Raddi
▶︎
MDS 2025: Plenary Session 7: Treatment Low Risk MDS (Part 2)
▶︎
MDS 2025: Plenary Session 8: Treatment High Risk
▶︎
Treating MDS - Understanding the Wait and Preparing to Act
▶︎
Understanding Lower Risk MDS What Are My Options
▶︎
Diagnosing MDS
▶︎
Trump Crashes the NBA Finals Party, Throws Unhinged Tantrum on Meet the Press: A Closer Look
▶︎
Scott Pelley on His Firing and the ‘Massacre’ at ‘60 Minutes’ | The Interview
▶︎
What is SonarQube | Introduction SonarQube | SonarQube Tutorial | SonarQube Basics | Intellipaat
▶︎
MDS 2025: Keynote Lecture
▶︎
Patient/Caregiver Stories - Living with MDS
▶︎
🩸 Phlebotomy Technician Practice Quiz – with Nurse Eunice! 🎯
▶︎
What do tech pioneers think about the AI revolution? - The Engineers, BBC World Service
▶︎
Management of Low Risk MDS with Dr. Mikkael Sekeres
▶︎
2025 Breakthrough! Reverse Disc Degeneration & End Spine Pain Fast
▶︎
Gil Strang's Final 18.06 Linear Algebra Lecture
▶︎
Neutropenia - Mayo Clinic
▶︎
Momentum in MDS: Making Progress and Shaping a Better Future
▶︎
MDS 2025: Workshop - MDS Treatment (Part 2)
▶︎
Thrombocytopenia in low-risk MDS
▶︎